Claims
- 1. Nucleic acid that comprises
a. The nucleotide sequence that is shown in Seq ID NO 1 b. A nucleotide sequence that corresponds to a sequence from a. within the scope of the degeneration of the genetic code or c. A nucleotide sequence that hybridizes with the sequences from a. or b. under stringent conditions with the function of a human ARL-2 protein.
- 2. Nucleic acid according to claim 1 that comprises a protein-coding section of the nucleic acid sequence that is shown in Seq ID NO 1.
- 3. Nucleic acid that codes for a polypeptide with the amino acid sequence that is shown in Seq ID NO 2.
- 4. Polypeptides coded by a nucleic acid according to one of claims 1-3.
- 5. Polypeptide that comprises the amino acid sequence that is shown in Seq ID NO 2 or portions thereof.
- 6. Use of a polypeptide according to claims 4 and 5 or of portions of this polypeptide for the production of antibodies.
- 7. Antibodies against a polypeptide according to one of claims 4 and 5.
- 8. Use of a probe with nucleic acid sequences that are complementary to the nucleic acid sequences according to claims 1-3 for the production of a reagent for detecting the presence of mRNA and, according to one of claims 1-3, in cells.
- 9. Antisense molecule that is directed against the nucleic acid according to claim 1.
- 10. Vector that contains at least one copy of a nucleic acid according to one of claims 1-3.
- 11. Cell that is transfixed with a nucleic acid according to one of claims 1-3 or with a vector according to claim 9.
- 12. Use of a cell according to claim 11 for the expression of the nucleic acid according to one of claims 1-3.
- 13. Use of
a. A nucleic acid according to one of claims 1 to 3, b. A polypeptide according to one of claims 4 and 5 or c. A cell according to claim 11 for identifying effectors of a polypeptide according to claim 4 or 5.
- 14. Use of a nucleic acid according to claims 1 to 3 or a polypeptide according to claims 4 and 5 of the antibody according to claim 7 or an antisense molecule according to claim 9 as a target substance for the production of an agent for diseases that are causally associated with the ARL-2 gene and/or protein.
- 15. Test system for identifying effectors of a polypeptide according to claim 4 or 5, whereby a polypeptide according to the invention is incubated as a complete or partial sequence of it with a modulator (effector), and the amounts of reduced aldehydes and ketones are measured.
- 16. Test system according to claim 14 or 15, whereby the effectors inhibit or activate the aldehyde- and ketone-reducing activity.
- 17. Test system for identifying effectors of the enzyme activity of the polypeptide of the invention according to claim 15 in a cell of the invention, whereby the amount of reduced aldehydes and ketones is measured.
- 18. Test system for identifying effectors of the anti-apoptosis polypeptide function of the invention according to claim 15.
- 19. Process for the preparation of a pharmaceutical agent, whereby
a. Substances with a test system according to claims 15, 16 and 17 are brought into contact. b. The action of the substances on the test system in comparison to controls is measured, c. A substance that in step b. shows a modulation of the activity of the polypeptide according to claim 4 or 5 is identified, d. And the substance that is identified in step c. is mixed with the formulation substances that are commonly used in pharmaceutics.
- 20. DNA chip, characterized in that at least one oligonucleotide is immobilized, which corresponds to the complete cDNA sequence or a partial sequence or a complementary sequence to the one described in Seq ID NO 1.
- 21. Use of a DNA chip according to claim 20 for diagnosis of fertility disorders.
Priority Claims (1)
Number |
Date |
Country |
Kind |
101 52 598.2 |
Oct 2001 |
DE |
|
Parent Case Info
[0001] This application claims the benefit of the filing date of U.S. Provisional Application Serial No. 60/331,531 filed Nov. 19, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60331531 |
Nov 2001 |
US |